摘要
目的探讨表阿霉素联合XELOX(奥沙利铂联合希罗达)治疗晚期胃癌的疗效及安全性。方法收集我院2006年6月～2010年12月采用表阿霉素联合XELOX方案(即EOX方案)治疗的晚期胃癌进行回顾性分析,并与奥沙利铂联合希罗达化疗方案(单纯XELOX方案)进行比较。EOX组54例,XELOX组66例。结果 EOX方案组总有效率为38.9%(21/54),XELOX方案组总有效率36.4%(24/66),两组间无显著性差异(P>0.05);XELOX方案组手足综合征的发病率较EOX方案组高,但大多都为Ⅰ～Ⅱ度反应,而Ⅲ～Ⅳ度骨髓抑制、消化道反应、脱发的发病率较EOX低,两组差异有统计学意义(P<0.05)。结论表阿霉素联合XELOX方案治疗晚期胃癌的疗效与单纯XELOX方案治疗的疗效相近,毒副作用可耐受,对于体质较弱或对多次化疗反应后耐受性较差的患者,可能更适合单纯XELOX化疗方案。
Objective To compare the efficacy and toxicity of the regimen of EOX（epirubiein,oxaliplatin and xeloda）with XELOX（oxaliplatin,xeloda）in treatment of patients with advanced gastric cancer.Methods Data of patients with advanced gastric cancer treated with EOX（n=54）from Jun 2006 to Dec 2010 were retrospectively analysed and compared with those treated with XELOX（n=66）.Results The overall response rate was 38.9% in EOX group and 36.4% in XELOX group（P〈0.05）.The main complication was hand-foot syndrome（gradeⅠ～Ⅱ）in XELOX group and leukopenia（gradeⅢ～Ⅳ）,nausea,vomiting,and alopecie in EOX group（P〈0.05）.Conclusion EOX regimen is as effective as XELOX in the treatment of advanced gastric cancer with tolerable toxicities.However,XELOX regimen may be better suitable for the elder patients and weaker after chemotherapies.
出处
《中国现代医药杂志》
2011年第8期4-6,共3页
Modern Medicine Journal of China
基金
国家自然科学基金资助项目(编号:30760239)
